arrow
T

Thi H. O. Nguyen

peter doherty institute for infection and immunity
H指数:44
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD4+ T-cell responses directed towards A/H5N1-derived haemagglutinin peptides increase in patients with seasonal influenza A virus infection

CD4<sup>+</sup> T细胞对A/H5N1来源的血凝素肽的应答在季节性甲型流感病毒感染患者中增加

2026-09-230
OAAI
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses

历史性的1994年流感疫苗队列定义了针对未来甲型和乙型流感病毒的抗体和B细胞反应的广度

2026-04-010
PRE
High expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures

白细胞介素-18受体α的高表达与严重呼吸道病毒性疾病相关,并定义了具有降低细胞毒性特征的记忆性T细胞。

2025-11-240
OAAI
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination

实体瘤恶性患者中失调的炎症塑造了针对COVID-19疫苗接种的多功能抗体反应

2025-10-060
OA
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial

流感特异性T细胞对疫苗接种的反应与基础血液恶性肿瘤无关:一项随机流感疫苗接种试验的分析

2025-07-010
PRE
Molecular determinants of cross-strain influenza A virus recognition by αβ T cell receptors

αβ T细胞受体跨菌株识别甲型流感病毒的分子决定因素

2025-02-210
PRE
SARS- CoV-2-specific CD8+T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years

来自长COVID患者的传染性非典型肺炎CoV-2-specific CD8 T细胞建立并维持效应子表型和关键TCR特征超过2年

2024-09-160
OAAI
CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age

CD8 T细胞对跨解剖部位和年龄的保守乙型流感病毒表位的反应

2024-04-291
OAAI
Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine
2024-02-203
OAAI
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
2023-12-015
OAAI
Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
2023-11-022
OAAI
Long-term safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or >56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
2023-11-011
OAAI
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan

老年人的新生儿和儿童样分子特征源于人类寿命的TCR变化

2023-09-257
OAAI
Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19

从新型冠状病毒肺炎中恢复的住院第一民族的广谱SARS-CoV-2-specific免疫力

2023-09-191
OAAI
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities
2023-05-2913
OAAI
CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity

抗原呈递细胞的CD4 T细胞校准优化抗病毒CD8 T细胞免疫

2023-05-1511
OA